Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer
2008

TMPRSS2-ERG Gene Fusion and Prostate Cancer Outcomes

Sample size: 372 publication Evidence: moderate

Author Information

Author(s): FitzGerald Liesel M, Agalliu Ilir, Johnson Karynn, Miller Melinda A, Kwon Erika M, Hurtado-Coll Antonio, Fazli Ladan, Rajput Ashish B, Gleave Martin E, Cox Michael E, Ostrander Elaine A, Stanford Janet L, Huntsman David G

Primary Institution: Fred Hutchinson Cancer Research Center

Hypothesis

The TMPRSS2-ERG gene fusion may be used as a prognostic indicator for prostate cancer.

Conclusion

The presence of the TMPRSS2-ERG fusion was not significantly associated with prostate cancer-specific mortality, although there was a suggestive trend towards higher mortality in those with multiple copies of the fusion.

Supporting Evidence

  • 64.5% of tumors were negative for the TMPRSS2-ERG fusion.
  • 35.5% of tumors were positive for the TMPRSS2-ERG fusion.
  • No significant difference in survival was observed between fusion positive and negative cases.
  • Higher prostate cancer-specific deaths were observed in fusion positive cases (7.9% vs. 4.4%).
  • The TMPRSS2 SNP rs12329760 was positively associated with TMPRSS2-ERG fusion by translocation.

Takeaway

This study looked at a gene fusion in prostate cancer to see if it could help predict how aggressive the cancer is. They found it didn't really help with that, but having more copies of the fusion might mean worse outcomes.

Methodology

Fluorescent in situ hybridization (FISH) assays were used to assess TMPRSS2-ERG fusion status in prostate cancer cases, along with genotyping of SNPs in a subset of cases.

Limitations

Only 57% of cases could be scored for fusion status due to technical issues, and the study had limited power due to few prostate cancer-specific deaths.

Participant Demographics

Patients diagnosed with prostate cancer from January 1, 1993, to December 31, 1996, with a mean age of 61.2 years.

Statistical Information

P-Value

p = 0.05 for association with translocation; p = 0.03 for multiple copies.

Confidence Interval

95% CI = 0.22–3.93 for overall survival; 95% CI = 0.34–4.02 for adjusted survival.

Digital Object Identifier (DOI)

10.1186/1471-2407-8-230

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication